|Attendees queue out of the door to hear a panel discussion on alignment with commercialization|
In a panel session on alignment with commercialization, attendees at Cell Therapy Bioprocessing & Commercialization were quite literally queuing out of the door to hear the discussion.
Session chair Robert Preti PhD, president of PCT, a Caladrius Company, posed the question of whether a cell therapy product was the process. “Yes and no,” he said. “It’s actually much more than that. But what does define the product?”
He told attendees that a cell therapy product has to be “transformative, have a robust manufacturing process, have the right business model, optimize COGS, must be scalable, logistically practical, clinic friendly and reimbursable”. “Ultimately a product has to be deliverable,” he said.
However, he stressed that cell therapy products are difficult to deliver compared with a pill. “The benefit derived must overcome the natural tendency to prescribe what is easier to deliver (ie a pill).”
He said one of the main challenges in creating a commercial future for cell therapy was to change and improve the manufacturing model. “It’s a complicated model, but we know it needs to change. It’s an enormous challenge. A manual manufacturing process will fail,” he added.
He challenged the panel to answer how to prioritize improvements to the process “to limit the need to go backwards and repeat trials”.
Join the conversation on Twitter by following #IBC_CTB15
Share this article with your social network, just click below to share now!